NASDAQ:SGTX

Sigilon Therapeutics News Headlines

$12.92
-0.38 (-2.86 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.81
$13.86
50-Day Range
$13.05
$23.53
52-Week Range
$12.58
$54.32
Volume34,588 shs
Average Volume116,099 shs
Market Capitalization$407.35 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Sigilon Therapeutics (NASDAQ SGTX) News Headlines Today

SourceHeadline
Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business HighlightsSigilon Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
finance.yahoo.com - May 10 at 4:18 PM
Sigilon Therapeutics to Present at the BofA Securities 2021 Healthcare ConferenceSigilon Therapeutics to Present at the BofA Securities 2021 Healthcare Conference
finance.yahoo.com - May 6 at 8:41 AM
Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual MeetingSigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting
finance.yahoo.com - April 27 at 7:29 PM
Sigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare ConferenceSigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 8 at 7:30 AM
Tessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic DevelopmentTessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic Development
finance.yahoo.com - April 7 at 9:29 AM
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business HighlightsSigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
finance.yahoo.com - March 19 at 8:30 AM
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business HighlightsSigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
finance.yahoo.com - March 19 at 8:30 AM
Sigilon’s SIG-007 Granted Orphan Drug Designation By FDA; Shares Pop 6%Sigilon’s SIG-007 Granted Orphan Drug Designation By FDA; Shares Pop 6%
finance.yahoo.com - March 8 at 9:50 AM
Sigilon Therapeutics Fabry Disease Therapy Receives Orphan Drug Designation In USSigilon Therapeutics' Fabry Disease Therapy Receives Orphan Drug Designation In US
markets.businessinsider.com - March 7 at 7:26 AM
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry DiseaseSigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease
finance.yahoo.com - March 5 at 9:28 AM
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry DiseaseSigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease
finance.yahoo.com - March 5 at 9:28 AM
Sigilon Therapeutics to Present at Barclays Global Healthcare ConferenceSigilon Therapeutics to Present at Barclays Global Healthcare Conference
finance.yahoo.com - March 4 at 8:26 AM
Sigilon Therapeutics Announces Preclinical Data in Multiple Lysosomal Diseases at the 17th Annual WORLDSymposium™Sigilon Therapeutics Announces Preclinical Data in Multiple Lysosomal Diseases at the 17th Annual WORLDSymposium™
finance.yahoo.com - February 8 at 11:41 AM
Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
finance.yahoo.com - January 13 at 7:36 AM
Sigilon Therapeutics, Inc. (SGTX)Sigilon Therapeutics, Inc. (SGTX)
realmoney.thestreet.com - December 31 at 5:07 AM
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type ISigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
finance.yahoo.com - December 17 at 8:33 AM
Sigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional SharesSigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
benzinga.com - December 10 at 4:40 PM
Sigilon Therapeutics, Inc. Rings the Closing Bell in Celebration of its IPOSigilon Therapeutics, Inc. Rings the Closing Bell in Celebration of its IPO
nasdaq.com - December 10 at 4:40 PM
Sigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesSigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - December 10 at 4:40 PM
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.